A novel immunomodulatory and molecularly targeted strategy for refractory Hodgkin's lymphoma

Although Hodgkin's lymphoma (HL) was one of the first human cancers to be cured by chemotherapy, no new agents other than brentuximab vedotin (Adcetris®, CD 30 directed antibody drug conjugate) have received US Food and Drug Administration (FDA) approval for HL since 1977. Subsets of young adul...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbiah, Vivek, Brown, Robert E., McGuire, Mary F., Buryanek, Jamie, Janku, Filip, Younes, Anas, Hong, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2013
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960191/
https://www.ncbi.nlm.nih.gov/pubmed/24395633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960191/
https://www.ncbi.nlm.nih.gov/pubmed/24395633

Ejemplares similares